Literature DB >> 20386901

Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence.

Kazuhiro Kitajima1, Kayo Suzuki, Yuji Nakamoto, Yumiko Onishi, Setsu Sakamoto, Michio Senda, Masato Kita, Kazuro Sugimura.   

Abstract

PURPOSE: To evaluate low-dose non-enhanced CT (ldCT) and full-dose contrast-enhanced CT (ceCT) in integrated (18)F-fluorodeoxyglucose (FDG) PET/CT studies for restaging of uterine cancer.
METHODS: A group of 100 women who had undergone treatment for uterine cervical (n=55) or endometrial cancer (n=45) underwent a conventional PET/CT scans with ldCT, and then a ceCT scan. Two observers retrospectively reviewed and interpreted the PET/ldCT and PET/ceCT images in consensus using a three-point grading scale (negative, equivocal, or positive) per patient and per lesion. Final diagnoses were obtained by histopathological examination, or clinical follow-up for at least 6 months.
RESULTS: Patient-based analysis showed that the sensitivity, specificity and accuracy of PET/ceCT were 90% (27/30), 97% (68/70) and 95% (95/100), respectively, whereas those of PET/ldCT were 83% (25/30), 94% (66/70) and 91% (91/100), respectively. Sensitivity, specificity and accuracy did not significantly differ between two methods (McNemar test, p=0.48, p=0.48, and p=0.13, respectively). There were 52 sites of lesion recurrence: 12 pelvic lymph node (LN), 11 local recurrence, 8 peritoneum, 7 abdominal LN, 5 lung, 3 supraclavicular LN, 3 liver, 2 mediastinal LN, and 1 muscle and bone. The grading results for the 52 sites of recurrence were: negative 5, equivocal 0 and positive 47 for PET/ceCT, and negative 5, equivocal 4 and positive 43 for PET/ldCT, respectively. Four equivocal regions by PET/ldCT (local recurrence, pelvic LN metastasis, liver metastasis and muscle metastasis) were correctly interpreted as positive by PET/ceCT.
CONCLUSION: PET/ceCT is an accurate imaging modality for the assessment of uterine cancer recurrence. Its use reduces the frequency of equivocal interpretations.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20386901     DOI: 10.1007/s00259-010-1440-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  26 in total

Review 1.  Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography-clinical use, interpretation methods, diagnostic improvements.

Authors:  Christian Cohade; Richard L Wahl
Journal:  Semin Nucl Med       Date:  2003-07       Impact factor: 4.446

Review 2.  Concurrent PET/CT with an integrated imaging system: intersociety dialogue from the joint working group of the American College of Radiology, the Society of Nuclear Medicine, and the Society of Computed Body Tomography and Magnetic Resonance.

Authors:  R Edward Coleman; Dominique Delbeke; Milton J Guiberteau; Peter S Conti; Henry D Royal; Jeffrey C Weinreb; Barry A Siegel; Michael F Federle; David W Townsend; Lincoln L Berland
Journal:  J Nucl Med       Date:  2005-07       Impact factor: 10.057

3.  Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer.

Authors:  Anna C Pfannenberg; Philip Aschoff; Klaus Brechtel; Mark Müller; Roland Bares; Frank Paulsen; Jutta Scheiderbauer; Godehard Friedel; Claus D Claussen; Susanne M Eschmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08-01       Impact factor: 9.236

4.  Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence.

Authors:  Sandro Sironi; Maria Picchio; Claudio Landoni; Stefania Galimberti; Mauro Signorelli; Valentino Bettinardi; Patrizia Perego; Costantino Mangioni; Cristina Messa; Ferruccio Fazio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-16       Impact factor: 9.236

5.  Clinical impact of positron emission tomography or positron emission tomography/computed tomography in the posttherapy surveillance of endometrial carcinoma: evaluation of 88 patients.

Authors:  J-Y Park; E N Kim; D-Y Kim; J-H Kim; Y-M Kim; Y-T Kim; J-H Nam
Journal:  Int J Gynecol Cancer       Date:  2008-02-19       Impact factor: 3.437

6.  Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT?

Authors:  Niklaus G Schaefer; Thomas F Hany; Christian Taverna; Burkhardt Seifert; Katrin D M Stumpe; Gustav K von Schulthess; Gerhard W Goerres
Journal:  Radiology       Date:  2004-07-23       Impact factor: 11.105

7.  Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT.

Authors:  Kazuhiro Kitajima; Koji Murakami; Erena Yamasaki; Yasushi Domeki; Yasushi Kaji; Ichio Fukasawa; Noriyuki Inaba; Narufumi Suganuma; Kazuro Sugimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-17       Impact factor: 9.236

8.  Nodal status of malignant lymphoma in pelvic and retroperitoneal lymphatic pathways: comparison of integrated PET/CT with or without contrast enhancement.

Authors:  Tsuyoshi Morimoto; Ukihide Tateishi; Tetsuo Maeda; Yasuaki Arai; Yasuo Nakajima; E Edmund Kim
Journal:  Eur J Radiol       Date:  2007-09-27       Impact factor: 3.528

9.  Recurrent cervical carcinoma after radical hysterectomy.

Authors:  D M Larson; L J Copeland; C A Stringer; D M Gershenson; J M Malone; C L Edwards
Journal:  Gynecol Oncol       Date:  1988-07       Impact factor: 5.482

10.  The clinical impact of [(18)F]FDG PET/CT for the management of recurrent endometrial cancer: correlation with clinical and histological findings.

Authors:  Hyun Hoon Chung; Won Jun Kang; Jae Weon Kim; Noh-Hyun Park; Yong-Sang Song; June-Key Chung; Soon-Beom Kang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-08       Impact factor: 9.236

View more
  12 in total

Review 1.  Imaging of female pelvic malignancies regarding MRI, CT, and PET/CT : part 1.

Authors:  Kerstin A Brocker; Celine D Alt; Michael Eichbaum; Christof Sohn; Hans-Ulrich Kauczor; Peter Hallscheidt
Journal:  Strahlenther Onkol       Date:  2011-09-23       Impact factor: 3.621

2.  Improvements in PET Image Quality in Time of Flight (TOF) Simultaneous PET/MRI.

Authors:  Ryogo Minamimoto; Craig Levin; Mehran Jamali; Dawn Holley; Amir Barkhodari; Greg Zaharchuk; Andrei Iagaru
Journal:  Mol Imaging Biol       Date:  2016-10       Impact factor: 3.488

3.  Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen?

Authors:  Marius E Mayerhoefer; Matthias Schuetz; Silvia Magnaldi; Michael Weber; Siegfried Trattnig; Georgios Karanikas
Journal:  Eur Radiol       Date:  2011-11-12       Impact factor: 5.315

Review 4.  Present and future role of FDG-PET/CT imaging in the management of gynecologic malignancies.

Authors:  Kazuhiro Kitajima; Yasuhiko Ebina; Kazuro Sugimura
Journal:  Jpn J Radiol       Date:  2014-04-18       Impact factor: 2.374

5.  Imaging of endometrial and cervical cancer.

Authors:  Shilpa Patel; Sidath H Liyanage; Anju Sahdev; Andrea G Rockall; Rodney H Reznek
Journal:  Insights Imaging       Date:  2010-09-28

Review 6.  The role of FDG-PET/CT in gynaecological cancers.

Authors:  Andrea G Rockall; Susan Cross; Sean Flanagan; Elizabeth Moore; Norbert Avril
Journal:  Cancer Imaging       Date:  2012-03-05       Impact factor: 3.909

7.  Contrast-enhanced [18 F] fluorodeoxyglucose-positron emission tomography/computed tomography in clinical oncology: tumor-, site-, and question-based comparison with standard positron emission tomography/computed tomography.

Authors:  Silvia Morbelli; Raffaella Conzi; Claudio Campus; Giuseppe Cittadini; Irene Bossert; Michela Massollo; Giuseppe Fornarini; Iolanda Calamia; Cecilia Marini; Francesco Fiz; Chiara Ghersi; Lorenzo E Derchi; Gianmario Sambuceti
Journal:  Cancer Imaging       Date:  2014-04-22       Impact factor: 3.909

Review 8.  Role of 18F-FDG PET/CT in the carcinoma of the uterus: a review of literature.

Authors:  Alessandra Musto; Gaia Grassetto; Maria Cristina Marzola; Sotirios Chondrogiannis; Anna Margherita Maffione; Lucia Rampin; David Fuster; Francesco Giammarile; Patrick M Colletti; Domenico Rubello
Journal:  Yonsei Med J       Date:  2014-11       Impact factor: 2.759

Review 9.  The role of 18F-FDG PET CT in common gynaecological malignancies.

Authors:  Priya Narayanan; Anju Sahdev
Journal:  Br J Radiol       Date:  2017-08-22       Impact factor: 3.039

10.  Results of a Prospective Trial to Compare 68Ga-DOTA-TATE with SiPM-Based PET/CT vs. Conventional PET/CT in Patients with Neuroendocrine Tumors.

Authors:  Lucia Baratto; Akira Toriihara; Negin Hatami; Carina M Aparici; Guido Davidzon; Craig S Levin; Andrei Iagaru
Journal:  Diagnostics (Basel)       Date:  2021-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.